Contract # 36F79719D0049
Axolotl Graft™ is a dehydrated human amnion membrane allograft (dhAM) derived from the amniotic components of the placenta to advance soft tissue repair and reconstruction. It is classified as minimally manipulated under FDA regulation 21 CFR Part 1271 and section 361 of the PHS. Axolotl Biologix uses our proprietary BioSym™ process to manufacture Axolotl Graft™. The amniotic components used in Axolotl Graft™ creates a natural 3-D extracellular matrix scaffold for cellular attachment and creates an environment to promote cell migration and proliferation. Amniotic tissues are reported to contain cytokines and growth factors which stimulate protein and collagen synthesis, collagenase activity, and chemotaxis of fibroblasts and smooth muscle cells. Axolotl Graft™ functions as a bacteriostatic agent, which can inhibit the growth of bacteria at the wound site and reduce the rate of infection in chronic wounds. Axolotl Graft™ is immune-privileged, it lacks specific surface antigens, which makes it suitable for many different clinical applications.
• Human allograft under FDA regulation 21 CFR Part 1271 and section 361 of the PHS
• Immune privileged with anti-inflammatory and anti-bacterial properties
• Contains extracellular matrix components for cellular attachment and proliferation
• Dehydrated and terminally e-beam sterilized for an extended shelf life.
• Ease of use
Our tissue is recovered from living donors that are tested and qualified after a full-term pregnancy and during a scheduled C-section. Our processor is thorough in their screening and testing process to ensure patient safety.
Order Products by Product Code or Product Name
Name Code Size
Axolotl Graft™ - 1x2 AG02 2 cm2
Axolotl Graft™ - 2x3 AG06 6 cm2
Axolotl Graft™ - 4x4 AG16 16 cm2